08.07.20
DAPA-HF trial lead researcher in webinar on pioneering findings
A “highly respected” professor whose research is expected to have a significant impact on future diabetes treatments will discuss his findings during an online webinar for DPC.
Professor John McMurray led the DAPA-HF trial, which found that AstraZeneca’s dapagliflozin reduces new-onset of diabetes cases by almost a third among adults with heart failure.
This means that those with heart failure who were given the SGLT2 inhibitor during the trial had a 32 per cent lower risk of developing the condition over 18 months.
The Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow recently unveiled the findings from the study’s landmark Phase III at the 80th American Diabetes Association (ADA) Virtual Scientific Sessions.
REGISTER TO THIS FREE CPD ACCREDITED WEBINAR HERE
He will further discuss the study during this DPC Summer Forum session, entitled ‘DAFA-HF – ADA update and prescribing into practice’ happening on Wednesday 15th July from 7pm to 8pm.
He will be joined by Dr David Strain, Dr Marc Evans, Dr Jim Moore, Dr Kevin Fernando, Consultant Pharmacist Philip Newland-Jones and Diabetes Specialist Nurse Amanda Epps.
DPC Founder Maggie Meer said: “We are exceptionally honoured to have Professor John McMurray take part in our next DPC Summer Forum. He’s at the top of his game, having unveiled some major diabetes findings which will have a huge impact on treatment pathways in the future.
“He’s highly respected and the DAPA-HF is a major trial, so we’re thrilled that he’s agreed to participate and discuss his findings and thoughts on his very own research.”
The webinar will start at 7pm and prior registration is required.
DAFA-HF – ADA update and prescribing into practice
Wednesday 15th July
7pm to 8pm
REGISTER TO THIS FREE CPD ACCREDITED WEBINAR HERE